Evidence map›Paper›PMID 41644508›Full record

ArticleBone research2026

Sulfated chitosan mitigates acute lung injury induced bone loss via immunoregulation.

Yongxian Liu, Luli Ji, Fuwei Zhu, Jiaze Yu, Dongao Huang, Jingyuan Cui, Xiaogang Wang, Jing Wang, Changsheng Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yongxian Liu *The State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Luli Ji *The State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Fuwei ZhuThe State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Jiaze YuThe State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Dongao HuangThe State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Jingyuan CuiThe State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Xiaogang WangThe State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China. wangxiaogang@ecust.edu.cn.
Jing WangThe State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China. biomatwj@163.com.
Changsheng LiuEngineering Research Center for Biomedical Materials of the Ministry of Education, East China University of Science and Technology, Shanghai, China. liucs@ecust.edu.cn.ORCID 0000-0003-0509-7334

Funding

National Natural Science Foundation of China (National Science Foundation of China) T2288102
6 · The paper itself

Abstract

Respiratory inflammatory diseases disrupt bone metabolism and cause pathological bone loss. The lung-bone axis is established in chronic diseases like asthma and cystic fibrosis but is less studied in acute lung injury (ALI), recently implicated in COVID-19-induced bone loss. This study examined the effects of LPS-induced ALI on bone phenotype and explored the role of 2-N, 6-O sulfated chitosan (26SCS) in mitigating pneumonia-induced bone loss via inflammatory response modulation. Our findings show that 26SCS effectively reaches bone tissue after oral administration. It promotes macrophage polarization to the M2 phenotype, alleviating immune cascade reactions and inhibiting osteoclast-mediated bone resorption. Increased M2 macrophages support type H vessel formation, enhancing inflammatory bone vascularization. These effects foster a favorable osteogenic microenvironment and mitigate ALI-induced bone loss. While dexamethasone is effective in reducing inflammation, it can aggravate ALI-induced bone loss. Our research offers a therapeutic strategy targeting the lung-bone axis for inflammation-induced bone loss.

Indexed as

Acute Lung InjuryBone ResorptionChitosanAnimalsCOVID-19LipopolysaccharidesMacrophagesMaleMiceMice, Inbred C57BLOsteoclastsChitosanLipopolysaccharides

Identifiers

PMID41644508
PMCPMC12877068

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.